top of page

 A Primer on MDLs - FAQs

Basic MDL Statistics

Basic MDL Statistics

MDL Proceedings by Type.png

MDLs by the Numbers

As of April 15, 2019, 205 MDL proceedings were pending in federal courts across the country. The majority of these proceedings are products liability, antitrust, or miscellaneous.

 

Click on each image for an interactive version. 
 

MDL Proceedings by Total Actions (Histor

Products-Liability Proceedings

Looking at the total number of actions filed within these 205 MDL proceedings shows that between 92-95% of all the actions filed in MDLs are products liability.

​

New filings in MDLs currently make up between 15-21% of all new federal civil filings.

How Do Product-Liability MDLs End_.png

How Do Products-Liability Proceedings End?

Of the products-liability proceedings pending on the MDL docket in May of 2013, most ended in private, aggregate settlements.

Proceedings that principally allege economic harms are often certified as class actions.

Lead Lawyers & Repeat Players

Lead Lawyers

Judges aren't able to speak directly with every lawyer in massive multidistrict proceedings. So, they appoint lead lawyers on behalf of the plaintiffs.

​

The number of leaders varies by proceeding, with lead counsel as the most powerful position.

​

As indicated by the graphs below, both plaintiff and defense leadership positions tend to be populated by repeat players.

​

Click on the graph for an interactive version.

Leadership Appointments by MDL Proceedin

Some lawyers appear time and again as lead lawyers in MDL products-liability proceedings.

 

They are pivotal in negotiating and designing mass-tort deals.

​

Here are the major players within the book's dataset.

​

Click on the bubble chart for a list and an interactive version.

Repeat Players in MDL within the Dataset

Judges tend to appoint lawyers from the same plaintiff and defense law firms to lead products-liability MDLs.

​

Who are those go-to firms?

​

Here's a bubble chart of the law firms that were appointed the most frequently within the dataset.

​

Click on the chart for a list and an interactive version.

Repeat Players by Law Firm - clean.png

Products-liability proceedings are some of the largest proceedings in federal court.

​

Proceedings with the most actions include asbestos and the pelvic-mesh proceedings before Judge Joseph Goodwin.

​

Click on the bubble chart for a list and an interactive version.

MDL Proceeding by Size v.2.png
Settlement Provisions

Mass Tort Settlement Provisions

Mass Tort Deals marshals a wide array of empirical data on multidistrict litigation to suggest that the systemic lack of checks and balances for these cases may benefit everyone but the plaintiffs.

 

Analyzing mass-tort cases consolidated over 22 years and settled over 14, including the deals insiders negotiate, the “common-benefit” attorneys’ fees that the lead plaintiffs’ attorneys receive to run the litigation, and the judicial rulings, reveals a troubling pattern: repeat plaintiff and defense attorneys persistently benefit from the current system.

 

Defense lawyers are able to end sprawling lawsuits on their corporate client’s behalf while lead plaintiffs’ lawyers broker deals that reward them handsomely and sometimes pay litigants very little.

​

By identifying settlement provisions that one might argue principally benefit the repeat players, Mass Tort Deals examines the publicly available nonclass settlements these elite lawyers designed. All of those settlements can be downloaded by clicking on the links below.

 

Every settlement features at least one closure provision for corporate defendants (all listed and described below), and nearly all contain some provision that increases lead plaintiffs’ lawyers’ common-benefit fees.

 

Bargaining for attorneys’ fees with one’s opponent is a stark departure from traditional contingent-fee principles, which are designed to tie lawyers’ fees to their clients’ outcome. Based on the evidence available, there is reason to be concerned that when repeat players influence the practices and norms that govern multidistrict proceedings and settlement programs—when they “play for rules,” so to speak—the rules they develop may principally benefit them at plaintiffs' expense.

Screenshot 2019-04-13 13.53.26.png

Settlement Agreements

(Click below to view)

Lead Plaintiffs' Lawyers' Fees Negotiated with Defendant

84%

All Settlements Except NuvaRing and American Medical Systems (data unavailable)

Whatever money is left in a settlement fund after the program doles it out then reverts to the corporate defendant, which can incentivize defendants to craft strict recovery criteria.

All Settlements

If fewer than the desired percentage of plaintiffs enter the settlement program, the corporate defendant may call the deal off.  Required participation rates ranged from 85-100%

Yasmin/Yaz I & II, DePuy ASR I & II, Vioxx, NuvaRing, Actos, Zimmer Durom Hip Cup

Dealmakers jointly petition the judge to issue a census that requires all attorneys with a case in the MDL proceeding to register all their clients' state and federal claims, whether filed or unfiled, so that the corporate defendant can use that number as the denominator for calculating compliance with the walkaway percentage.

By plaintiffs' attorney: Propulsid I & II, Vioxx, Fosamax, American Medical Systems

By defendant: DePuy ASR I & II

By plaintiffs' attorney: Propulsid I & II, Vioxx, Fosamax, American Medical Systems

By defendant: DePuy ASR I & II

Mandatory: Propulsid I & II, Vioxx, Fosamax, American Medical Systems

Best efforts: Yasmin/Yaz I & II, DePuy ASR I & II, NuvaRing, Actos

All participating attorneys must recommend that all their clients enter into the settlement program.

DePuy ASR I & II, Zimmer Durom Hip Cup, Fosamax, American Medical Systems

By aiming to prevent new lawsuits from being fied once a settlement is announced, these provisions take various forms, such as reducing payouts to those without counsel on the settlemnett date, restricting lawyer advertising, or affirming that participating lawyers have no intent to solicit new clients.

Propulsid I & II, DePuy ASR I & II

Whatever money is left in a settlement fund after the program doles it out then reverts to the corporate defendant, which can incentivize defendants to craft strict recovery criteria.

Data in Mass Tort Deals

Index to Data Available in Mass Tort Deals

Screenshot 2019-04-12 13.24.41.png

Learn More

List of MDL Proceedings

Products-liability proceedings pending on the MDL docket as of May 2013

Data on Repeat Players

The password for this page is available to purchasers (page 5, footnote 4 of Mass Tort Deals).

Social Network Analysis

Links to in-depth views of the connctions between repeat players and MDL proceedings. Analysis by Dr. Margaret Williams

MDL Orders and Filings

All of the filings, transcripts, and orders collected as part of the analysis in Mass Tort Deals are available, searchable, and downloadable here.

bottom of page